肿瘤预防与治疗2019，Vol.32Issue(1)：30-37,8.DOI:10. 3969／j. issn. 1674-0904. 2019. 01. 005
EGFR突变阳性的晚期非小细胞肺癌交替使用EGFR-TKI及放化疗的回顾性研究
Retrospective Study of Alternated EGFR-TKI and Chemoradiotherapy for EGFR Mutation-positive Advanced Non-small Cell Lung Cancer
摘要
Abstract
Objective: To retrospectively observe the clinical efficacy and adverse effects of two sequential therapeutic modes, chemoradiotherapy-EGFR-TKI-chemoradiotherapy ( RCT-TKI-RCT) and EGFR-TKI-chemoradiotherapy-EGFR-TKI ( TKI-RCT-TKI), in advanced non-small cell lung cancer (NSCLC) patients with positive EGFR gene mutation. Methods:The information of 46 advanced NSCLC patients with positive EGFR gene mutation were collected. Twenty-six patients were treated with RCT-TKI-RCT and 20 patients with TKI-RCT-TKI. The patients in both groups were followed by second-line treatment after their first-line treatment failed, and their pro-gression-free survivals (PFS) 1 were recorded. After failure of second-line treatment, third-line treatment was performed and PFS2 was obtained. All patients were followed up until they died, and overall survival ( OS) of them was obtained. PFS1, PFS2, OS and adverse effects of both group were evaluated. Results: There were no statistically significant differences be-tween the two groups in clinical features, including age, KPS, history of tobacco use, EGFR mutation status and initial me-tastasis site. The median PFS1 of patients in the TKI-RCT-TKI group was longer than that of patients in the RCT-TKI-RCT group. The difference is not statistically significant (6. 6 months vs 5. 3 months, P=0. 077). The median PFS2 of the for-mer was also longer than that of the latter. The difference was not statistically significant (6. 3 months vs 5. 0 months, P=0. 646). There was also no statistically significant difference in median OS between the TKI-RCT-TKI group and the RCT-TKI-RCT group (21. 3 months vs 21. 0 months, P=0. 506). The adverse effects of the TKI-RCT-TKI group were relatively slighter, but there were no statistically significant differences between the two groups in diarrhea, rash, hematotoxicity ofⅢ~Ⅳ degree, nausea and vomiting etc. Conclusion: PFS1, PFS2 and OS of the TKI-RCT-TKI group were longer than those of the RCT-TKI-RCT group, and the adverse effects of the former were slighter.关键词
非小细胞肺癌/EGFR-TKI/放疗/化疗/靶向治疗Key words
Non-small cell lung cancer/ EGFR-TKI/ Radiotherapy/ Chemotherapy/ Targeted therapy分类
医药卫生引用本文复制引用
Rao Mingyue,Wen Qinglian,Lin Sheng,Zhang Jianwen,Liu Qiaoli,Ren Peirong,Wu Jingbo..EGFR突变阳性的晚期非小细胞肺癌交替使用EGFR-TKI及放化疗的回顾性研究[J].肿瘤预防与治疗,2019,32(1):30-37,8.基金项目
西南医科大学青年基金(编号:20130390) （编号:20130390）
西南医科大学附属医院青年基金(编号:14066) This study was supported by Youth Foundation of Southwest Medical University ( NO. 20130390 ) and Youth Foundation of the Affiliated Hospital of Southwest Medical University(NO. 14066) （编号:14066）
